Justin Zelin: Hey guys thanks for taking the question and congrats on the progress. I will add a question on 2735. So obviously, you are going to be looking at safety, tolerability, PKA and PD here. Do you think that you will be able to see some signs of efficacy in four weeks here or do you think you will probably need to look at a longer time period on drug to start seeing some weight loss?
Brian Lian: Hey Justin, that is a great question. I think 28-days is really hard to see weight loss in. So we are going to be looking most at tolerability, PK informing us for what sort of regimen we take forward into a Phase II study. When we look at the potential pharmacodynamic measures, body weight is of the greatest interest of people. And I think the hurdle we are really looking at there is if we can show efficacy that looks similar to a GLP-1 monoagonist, I think that would be pretty exciting. And generally, that is in the sub-2% range, 1% to 2% over 28-days. We feel that, that would be exciting because we know that we are hitting GIP and we know in the animals, we see a clear separation from GLP-1 monoagonist, and we believe that, that is going to augment the activity of GLP-1, but we just don’t know whether or not that is going to be fully observed or observable in a treatment course is short as 28-days.
So we are trying to be pretty conservative on the expectations for efficacy there since it is such a short study.
Justin Zelin: Great that makes sense for me. Thanks for taking the question.
Brian Lian: Thanks Justin.
Operator: The next question comes from Naz Rahman of Maxim Group. Please go ahead.
Nazibur Rahman: Hi guys, thanks for taking my question. And I had a few, but I will focus on 0214 kind of shifting a little bit. What the data expected later this year, could you just kind of walk us through what you are sort of hoping to see in the study or what you are looking for?
Brian Lian: Yes. With this study, we are going to be looking – it is a Phase Ib study. So we will look at safety and tolerability and PK in the patient population. We saw really encouraging tolerability and pharmacodynamic effects in shorter study in healthy volunteers, but they didn’t have adrenoleukodystrophy. So we will look at PK and see if there are any differences. And on the pharmacodynamic side, we will look at changes in very long chain fatty acids, which are believed to contribute to the course of disease in these patients. Those will be the main areas of focus.
Nazibur Rahman: Just could you remind us, are you looking at any like notable biomarkers in these patients?
Brian Lian: Yes. I think very long chain fatty as would be the key tie marker we would be looking at there. Yes.
Nazibur Rahman: Okay. Got it. On the study line, could you also remind us if you plan on enrolling the third cohort in the study?
Brian Lian: Oh, the third dosing cohort. Well, we have three cohorts now. It is a placebo and then 20 and 40. And when we have enough data to make a decision, we may or may not add a higher dose cohort.
Nazibur Rahman: Got it. And when you release the data, are you going to release the data from the cohort separately or are you just going to wait until you have data from all three core or lease ones?
Brian Lian: It is a parallel design. So we would really solve the data together.
Nazibur Rahman: Okay, got it. thanks for answering my questions.
Brian Lian: Thanks Naz.
